Mealey's (March 14, 2023, 2:08 PM EDT) -- NEW YORK — A federal district court did not err in ruling that a lead plaintiff in a securities class action against a medical device maker and certain of its senior executives failed to sufficiently plead scienter in alleging that the defendants violated federal securities laws by misrepresenting the likelihood of approval of the company’s cardiovascular therapy because none of the lead plaintiff’s allegations shows that the U.S. Food and Drug Administration required additional data from the company before voting against the company’s application, a Second Circuit U.S. Court of Appeals panel ruled March 13 in affirming....